行情

CPHI

CPHI

惠普森医药
AMEX

实时行情|Nasdaq Last Sale

0.5805
-0.0195
-3.25%
盘后: 0.5800 -0.0005 -0.09% 16:52 09/24 EDT
开盘
0.6000
昨收
0.6000
最高
0.6000
最低
0.5800
成交量
19.26万
成交额
--
52周最高
1.630
52周最低
0.3501
市值
2,529.79万
市盈率(TTM)
-6.7736
分时
5日
1月
3月
1年
5年
惠普森医药公司(CPHI.US)Q2营收240万美元，净亏损80万美元
惠普森医药公司(CPHI.US)Q2营收240万美元，净亏损80万美元
智通财经 · 08/16 03:04
简报-中国医药控股有限公司公布 2021 年第二季度财务业绩
reuters.com · 08/13 20:33
中国医药控股第二季度每股收益 (0.02) 美元，销售额从 377 万美元同比下降 240 万美元
China Pharma Holding (AMEX:CPHI) reported quarterly losses of $(0.02) per share. The company reported $2.40 million in sales this quarter. This is a 36.36 percent decrease over sales of $3.77 million the same period
Benzinga · 08/13 20:32
由于收入下降近 36%，中国医药转向第二季度净亏损
MT Newswires · 08/13 16:58
-- 盈利快报 (CPHI) 中国医药控股报告第二季度收入 240 万美元
MT Newswires · 08/13 16:39
中国医药坎地沙坦高血压产品通过生物等效性试验，公司拟申请国家药品监督管理局批准
China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that its Candesartan hypertension product passed key bioequivalence tests. The Company plans to use the results o...
PR Newswire · 08/05 13:00
中国医药将推出高纯度 NMN+PQQ 产品
China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced plans to launch a highly purified NMN+PQQ product following the recent successful completion of a pilot scale tes...
PR Newswire · 06/09 12:00
BRIEF-China Pharma Holdings Posts Q1 Loss Per Share Of $0.02
reuters.com · 05/14 21:22
更多
财务预测
暂无数据
利润表更多
净利润（美元）
同比（%）
资产负债表更多
总资产（美元）
总负债（美元）
资产负债率（%）
现金流表更多
经营现金流（美元）
同比（%）
了解CPHI最新的财务预测，通过CPHI每股收益，每股净资产，每股现金流等数据分析惠普森医药近期的经营情况，然后做出明智的投资选择。
暂无数据
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-2.13%
制药与医学研究
-1.02%
高管信息
Chairman/President/Chief Executive Officer/Chief Financial Officer/Director
Zhilin Li
Director
Heung Tsui
Independent Director
Gene Bennett
Independent Director
Baowen Dong
Independent Director
Yingwen Zhang
暂无数据
  • 全部
  • 财务报告
  • 内部人交易
更多
CPHI 简况
China Pharma Holdings, Inc. is a holding company. The Company conducts its production, marketing, finance, development and administrative activities through its subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd. (Helpson) in the People's Republic of China (PRC). It is engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with various diseases and medical conditions in the PRC. It manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, oral solutions and granules. Its pharmaceutical products are sold on a prescription basis and are approved by the China Food and Drug Administration (the CFDA). The Company manufactured over 20 pharmaceutical products for various diseases and medical indications. It offers products for Central Nervous System (CNS) and Cerebral-Cardiovascular Diseases, Anti-infection and Respiratory Diseases, Digestive Diseases and Others.

微牛提供China Pharma Holdings, Inc.(AMEX-CPHI)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CPHI股票新闻，以帮助您做出投资决策。

模拟交易：模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CPHI股票基本功能。